Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

Scott R. Anderson; Malek Ayoub; Sarah Coats; Scott McHenry; Tingyi Tan; Parakkal Deepak

doi:10.14309/ajg.0000000000003208

Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

Scott R. Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

INTRODUCTION:The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.METHODS:Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.RESULTS:Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.DISCUSSION:GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.

Original language	English
Pages (from-to)	1152-1155
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	120
Issue number	5
DOIs	https://doi.org/10.14309/ajg.0000000000003208
State	Published - May 1 2025

Keywords

effectiveness
glucagon-like peptide-1 receptor agonists
inflammatory bowel disease
safety
weight loss

Access to Document

10.14309/ajg.0000000000003208

Cite this

@article{423a8aec8f684a9a89be9908b5341249,

title = "Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease",

abstract = "INTRODUCTION:The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.METHODS:Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.RESULTS:Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.DISCUSSION:GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.",

keywords = "effectiveness, glucagon-like peptide-1 receptor agonists, inflammatory bowel disease, safety, weight loss",

author = "Anderson, {Scott R.} and Malek Ayoub and Sarah Coats and Scott McHenry and Tingyi Tan and Parakkal Deepak",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 by The American College of Gastroenterology.",

year = "2025",

month = may,

day = "1",

doi = "10.14309/ajg.0000000000003208",

language = "English",

volume = "120",

pages = "1152--1155",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

number = "5",

}

TY - JOUR

T1 - Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

AU - Anderson, Scott R.

AU - Ayoub, Malek

AU - Coats, Sarah

AU - McHenry, Scott

AU - Tan, Tingyi

AU - Deepak, Parakkal

PY - 2025/5/1

Y1 - 2025/5/1

N2 - INTRODUCTION:The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.METHODS:Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.RESULTS:Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.DISCUSSION:GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.

AB - INTRODUCTION:The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.METHODS:Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.RESULTS:Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.DISCUSSION:GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.

KW - effectiveness

KW - glucagon-like peptide-1 receptor agonists

KW - inflammatory bowel disease

KW - safety

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=85213421715&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000003208

DO - 10.14309/ajg.0000000000003208

M3 - Article

C2 - 39717004

AN - SCOPUS:85213421715

SN - 0002-9270

VL - 120

SP - 1152

EP - 1155

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 5

ER -

Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this